Bortezomib-based chemotherapy for light chain deposition disease presenting as acute renal failure

Helen Gharwan, Cristina Truica

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

We report a case of kappa light chain deposition disease (LCDD) associated with multiple myeloma in a patient presenting with acute renal failure, 2+ proteinuria and hypercalcemia. Serum protein electrophoresis showed an M-spike at 0.1 g/dL. 24-h urine protein electrophoresis showed Bence-Jones proteinuria of 3.8 g. Serum-free light chain assay found excess kappa chains at 3080 mg/L, with normal lambda and an elevated kappa:lambda ratio of 124.7. A kidney biopsy revealed kappa light chain nephropathy with PAS-negative tubular casts in the cortex and outer medulla. Bone marrow biopsy showed 15% kappa-restricted plasma cells. Serum beta-2 microglobulin level was elevated at 7.94 mg/dL. The patient received a 3-day course of plasmapheresis followed by eight cycles of bortezomib (Velcade®), liposomal doxorubicin, and dexamethasone (VDD) and did not require hemodialysis. As partial response was not achieved, treatment was continued with three cycles of bortezomib, cyclophosphamide, dexamethasone, and thalidomide, followed by thalidomide maintenance at 100 mg daily. Thirty-two months after the diagnosis, the patient's renal function was improved and he achieved a partial response. This case underlines the feasibility and effectiveness of bortezomib-based chemotherapy in the treatment of LCDD with severe renal dysfunction.

Original languageEnglish (US)
Pages (from-to)1197-1201
Number of pages5
JournalMedical Oncology
Volume29
Issue number2
DOIs
StatePublished - Jun 1 2012

Fingerprint

Acute Kidney Injury
Light
Drug Therapy
Thalidomide
Kidney
Proteinuria
Dexamethasone
Electrophoresis
Biopsy
beta 2-Microglobulin
Plasmapheresis
Hypercalcemia
Plasma Cells
Serum
Multiple Myeloma
Cyclophosphamide
Renal Dialysis
Blood Proteins
Bone Marrow
Maintenance

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research
  • Hematology
  • Medicine(all)

Cite this

@article{6ccbec4c83914770b2a62872d729b701,
title = "Bortezomib-based chemotherapy for light chain deposition disease presenting as acute renal failure",
abstract = "We report a case of kappa light chain deposition disease (LCDD) associated with multiple myeloma in a patient presenting with acute renal failure, 2+ proteinuria and hypercalcemia. Serum protein electrophoresis showed an M-spike at 0.1 g/dL. 24-h urine protein electrophoresis showed Bence-Jones proteinuria of 3.8 g. Serum-free light chain assay found excess kappa chains at 3080 mg/L, with normal lambda and an elevated kappa:lambda ratio of 124.7. A kidney biopsy revealed kappa light chain nephropathy with PAS-negative tubular casts in the cortex and outer medulla. Bone marrow biopsy showed 15{\%} kappa-restricted plasma cells. Serum beta-2 microglobulin level was elevated at 7.94 mg/dL. The patient received a 3-day course of plasmapheresis followed by eight cycles of bortezomib (Velcade{\circledR}), liposomal doxorubicin, and dexamethasone (VDD) and did not require hemodialysis. As partial response was not achieved, treatment was continued with three cycles of bortezomib, cyclophosphamide, dexamethasone, and thalidomide, followed by thalidomide maintenance at 100 mg daily. Thirty-two months after the diagnosis, the patient's renal function was improved and he achieved a partial response. This case underlines the feasibility and effectiveness of bortezomib-based chemotherapy in the treatment of LCDD with severe renal dysfunction.",
author = "Helen Gharwan and Cristina Truica",
year = "2012",
month = "6",
day = "1",
doi = "10.1007/s12032-011-9938-4",
language = "English (US)",
volume = "29",
pages = "1197--1201",
journal = "Medical Oncology",
issn = "1357-0560",
publisher = "Humana Press",
number = "2",

}

Bortezomib-based chemotherapy for light chain deposition disease presenting as acute renal failure. / Gharwan, Helen; Truica, Cristina.

In: Medical Oncology, Vol. 29, No. 2, 01.06.2012, p. 1197-1201.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Bortezomib-based chemotherapy for light chain deposition disease presenting as acute renal failure

AU - Gharwan, Helen

AU - Truica, Cristina

PY - 2012/6/1

Y1 - 2012/6/1

N2 - We report a case of kappa light chain deposition disease (LCDD) associated with multiple myeloma in a patient presenting with acute renal failure, 2+ proteinuria and hypercalcemia. Serum protein electrophoresis showed an M-spike at 0.1 g/dL. 24-h urine protein electrophoresis showed Bence-Jones proteinuria of 3.8 g. Serum-free light chain assay found excess kappa chains at 3080 mg/L, with normal lambda and an elevated kappa:lambda ratio of 124.7. A kidney biopsy revealed kappa light chain nephropathy with PAS-negative tubular casts in the cortex and outer medulla. Bone marrow biopsy showed 15% kappa-restricted plasma cells. Serum beta-2 microglobulin level was elevated at 7.94 mg/dL. The patient received a 3-day course of plasmapheresis followed by eight cycles of bortezomib (Velcade®), liposomal doxorubicin, and dexamethasone (VDD) and did not require hemodialysis. As partial response was not achieved, treatment was continued with three cycles of bortezomib, cyclophosphamide, dexamethasone, and thalidomide, followed by thalidomide maintenance at 100 mg daily. Thirty-two months after the diagnosis, the patient's renal function was improved and he achieved a partial response. This case underlines the feasibility and effectiveness of bortezomib-based chemotherapy in the treatment of LCDD with severe renal dysfunction.

AB - We report a case of kappa light chain deposition disease (LCDD) associated with multiple myeloma in a patient presenting with acute renal failure, 2+ proteinuria and hypercalcemia. Serum protein electrophoresis showed an M-spike at 0.1 g/dL. 24-h urine protein electrophoresis showed Bence-Jones proteinuria of 3.8 g. Serum-free light chain assay found excess kappa chains at 3080 mg/L, with normal lambda and an elevated kappa:lambda ratio of 124.7. A kidney biopsy revealed kappa light chain nephropathy with PAS-negative tubular casts in the cortex and outer medulla. Bone marrow biopsy showed 15% kappa-restricted plasma cells. Serum beta-2 microglobulin level was elevated at 7.94 mg/dL. The patient received a 3-day course of plasmapheresis followed by eight cycles of bortezomib (Velcade®), liposomal doxorubicin, and dexamethasone (VDD) and did not require hemodialysis. As partial response was not achieved, treatment was continued with three cycles of bortezomib, cyclophosphamide, dexamethasone, and thalidomide, followed by thalidomide maintenance at 100 mg daily. Thirty-two months after the diagnosis, the patient's renal function was improved and he achieved a partial response. This case underlines the feasibility and effectiveness of bortezomib-based chemotherapy in the treatment of LCDD with severe renal dysfunction.

UR - http://www.scopus.com/inward/record.url?scp=84864002302&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864002302&partnerID=8YFLogxK

U2 - 10.1007/s12032-011-9938-4

DO - 10.1007/s12032-011-9938-4

M3 - Article

VL - 29

SP - 1197

EP - 1201

JO - Medical Oncology

JF - Medical Oncology

SN - 1357-0560

IS - 2

ER -